Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma

Scott T. Tagawa, MD
Published: Monday, Jun 17, 2019



Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses next steps with sacituzumab govitecan in advanced urothelial carcinoma.

Preliminary data from a phase I/II study presented at the 2019 Genitourinary Cancers Symposium were promising, but they were limited to 45 patients, Tagawa says. Also, only a minority of patients received platinum-based chemotherapy and a PD-1 inhibitor as prior therapy. As such, researchers have launched the phase II TROPHY-U-01 (NCT03547973), which is evaluating the agent in patients with advanced disease who have had platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.

In this study, there is no limit on prior lines of therapy, Tagawa notes. Researchers hope to confirm the encouraging overall response rate seen in the initial trial. There will also be an exploratory analysis of patients who are cisplatin-ineligible and received an immune checkpoint inhibitor.
SELECTED
LANGUAGE


Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses next steps with sacituzumab govitecan in advanced urothelial carcinoma.

Preliminary data from a phase I/II study presented at the 2019 Genitourinary Cancers Symposium were promising, but they were limited to 45 patients, Tagawa says. Also, only a minority of patients received platinum-based chemotherapy and a PD-1 inhibitor as prior therapy. As such, researchers have launched the phase II TROPHY-U-01 (NCT03547973), which is evaluating the agent in patients with advanced disease who have had platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.

In this study, there is no limit on prior lines of therapy, Tagawa notes. Researchers hope to confirm the encouraging overall response rate seen in the initial trial. There will also be an exploratory analysis of patients who are cisplatin-ineligible and received an immune checkpoint inhibitor.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x